Greater Cannabis Company (GCAN) EBITDA Margin (2017 - 2021)
Greater Cannabis Company's (GCAN) quarterly EBITDA Margin came in at 494.65% in Q2 2021, down 32417.0% year-on-year from N/an in Q2 2020, and down 190.16% quarter-over-quarter from 170.47% in Q2 2020.
Greater Cannabis Company (GCAN) EBITDA Margin (2017 - 2021) Analysis & Trends
Greater Cannabis Company's EBITDA Margin history runs 5 years deep, the most recent figure standing at 494.65% for Q2 2021.
- On a quarterly basis, EBITDA Margin fell 32417.0% year-over-year to 494.65% in Q2 2021; TTM through Dec 2021 was 2716.91%, a 215651.0% decrease from a year earlier, with the FY2021 full-year figure at 2716.91%, down 210402.0% from the prior year.
- EBITDA Margin declined to 494.65% in Q2 2021 per GCAN's latest filing, from 170.47% in the prior quarter.
- Across five years, EBITDA Margin topped out at 99.52% in Q1 2018 and bottomed at 43656.16% in Q2 2017.
- The 5-year median for EBITDA Margin is 494.65% (2021), against an average of 8931.99%.
- Across the five-year window, EBITDA Margin soared 4375550 bps in 2018 and plunged 423968 bps in 2019, its largest moves.
- Year by year, EBITDA Margin stood at 28856.62% in 2017, then jumped by 100 bps to 87.65% in 2018, then slumped by 4837 bps to 4327.33% in 2019, then jumped by 96 bps to 170.47% in 2020, then plunged by 190 bps to 494.65% in 2021.
- Per Business Quant, the three latest GCAN EBITDA Margin figures stand at 494.65% (Q2 2021), 170.47% (Q2 2020), and 4327.33% (Q4 2019).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -494.65% |
| Jun 30, 2020 | -170.47% |
| Dec 31, 2019 | -4,327.33% |
| Sep 30, 2019 | -2,993.85% |
| Dec 31, 2018 | -87.65% |
| Jun 30, 2018 | 99.34% |
| Mar 31, 2018 | 99.52% |
| Sep 30, 2017 | -28,856.62% |
| Jun 30, 2017 | -43,656.16% |